Cover Image

Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors

Since prostate-specific membrane antigen (PSMA) is up-regulated in nearly all stages of prostate cancer (PCa), PSMA can be considered as a viable diagnostic biomarker and treatment target in PCa. This project is focused on the development and evaluation of a series of compounds directed against PSMA...

Full description

Saved in:
Bibliographic Details
Main Authors: Benes̆ová, Martina (Author) , Bauder-Wüst, Ulrike (Author) , Schäfer, Martin (Author) , Klika, Karel D. (Author) , Mier, Walter (Author) , Haberkorn, Uwe (Author) , Kopka, Klaus (Author) , Eder, Matthias (Author)
Format: Article (Journal)
Language:English
Published: February 15, 2016
In: Journal of medicinal chemistry
Year: 2016, Volume: 59, Issue: 5, Pages: 1761-1775
ISSN:1520-4804
DOI:10.1021/acs.jmedchem.5b01210
Online Access:Verlag, Volltext: https://doi.org/10.1021/acs.jmedchem.5b01210
Verlag, Volltext: https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01210
Get full text
Author Notes:Martina Benešová, Ulrike Bauder-Wüst, Martin Schäfer, Karel D. Klika, Walter Mier, Uwe Haberkorn, Klaus Kopka, and Matthias Eder
Description
Summary:Since prostate-specific membrane antigen (PSMA) is up-regulated in nearly all stages of prostate cancer (PCa), PSMA can be considered as a viable diagnostic biomarker and treatment target in PCa. This project is focused on the development and evaluation of a series of compounds directed against PSMA. The modifications to the linker are designed to improve the binding potential and pharmacokinetics for theranostic application. In addition, the results help to further elucidate the structure-activity relationships (SAR) of the resulting PSMA inhibitors. Both in vitro and in vivo experiments of 18 synthesized PSMA inhibitor variants showed that systematic chemical modification of the linker has a significant impact on the tumor-targeting and pharmacokinetic properties. This approach can lead to an improved management of patients suffering from recurrent prostate cancer by the use of one radiolabeling precursor, which can be radiolabeled either with 68Ga for diagnosis or with 177Lu or 225Ac for therapy.
Item Description:Gesehen am 21.02.2020
Physical Description:Online Resource
ISSN:1520-4804
DOI:10.1021/acs.jmedchem.5b01210

Similar Items